Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide

Enzalutamide, apalutamide, and darolutamide are currently recommended for patients with non‐metastatic castration‐resistant prostate cancer (nmCRPC), but cross‐resistance of androgen receptor‐axis‐targeted therapies (ARAT) occurs. Because darolutamide has a distinct chemical structure to other non‐s...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujmoto, Saizo, Fujita, Kazutoshi, Nishimoto, Mitsuhisa, Hamaguchi, Mamoru, Kuwahara, Ken, Hashimoto, Mamoru, Adomi, Shogo, Minami, Takafumi, Nozawa, Masahiro, Yoshimura, Kazuhiro, Uemura, Hirotsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
BRIEF COMMUNICATION
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939194/
https://www.ncbi.nlm.nih.gov/pubmed/36043427
http://dx.doi.org/10.1002/cam4.5189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939194/
https://www.ncbi.nlm.nih.gov/pubmed/36043427
http://dx.doi.org/10.1002/cam4.5189

Ejemplares similares